Sabby Management’s Capricor Therapeutics CAPR Stock Holding History

Sabby Management’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-2,420	Closed	-$20K	–	174
2017 Q2	$20K	Sell	2,420 -21,339	-90%	-$390K	﹤0.01%	210
2017 Q1	$791K	Sell	23,759 -13,446	-36%	-$373K	0.04%	145
2016 Q4	$990K	Buy	37,205 +1,461	+4%	+$43.7K	0.06%	145
2016 Q3	$1.18M	Buy	35,744 +17,536	+96%	+$659K	0.04%	168
2016 Q2	$719K	Sell	18,208 -2,000	-10%	-$70.6K	0.04%	193
2016 Q1	$513K	Buy	20,208 +1,642	+9%	+$39.8K	0.03%	210
2015 Q4	$570K	Sell	18,566 -6,479	-26%	-$258K	0.03%	228
2015 Q3	$1.01M	Sell	25,045 -795	-3%	-$35.4K	0.04%	233
2015 Q2	$1.3M	Buy	+25,840	New	+$1.62M	0.05%	206

Other funds holding CAPR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CBA

Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return

BAM

Belpointe Asset Management Reno, Nevada $2.74B AUM 20.71% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Apriem Advisors Irvine, California $1.05B AUM 22.09% 1-Year Est. Return

FWM

Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

GPCM

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Sabby Management's CAPR Position: Q3 2017 in Review

Sabby Management sold out of Capricor Therapeutics (CAPR) in Q3 2017, closing a stake of 2,420 shares — an estimated $20K sold.

Sabby Management first reported a position in CAPR in Q2 2015 and held it in 9 quarters. The position peaked at $1.3M in Q2 2015. 19 funds tracked by Wall St. Rank hold CAPR as of Q3 2017.

Sabby Management reported no remaining Capricor Therapeutics position as of Q3 2017 after selling out during the quarter.
Sabby Management sold 2,420 Capricor Therapeutics shares in Q3 2017, an estimated $20K.
Sabby Management first reported a position in Capricor Therapeutics in Q2 2015 and held it in 9 quarters.
Sabby Management's Capricor Therapeutics position peaked at $1.3M in Q2 2015.
19 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2017.

Based on Sabby Management's 13F filing for Q3 2017, filed 14 Nov 2017.